Skip to content
OpenCapital
Earnings
Screener
Charts
Portfolio
Pricing
Connect your AI
Get started
Toggle navigation menu
MAZE
MAZE
EBITDA margin
EBITDA margin at other companies
Vertex Pharmaceuticals
VRTX
40.1%
+36.9pp
Septerna, Inc.
SEPN
-74.8%
-37.3pp
Stoke Therapeutics, Inc.
STOK
-572.1%
-593pp
Zymeworks
ZYME
-132.6%
+10.5pp
Nurix Therapeutics, Inc.
NRIX
-427.3%
+42.6pp
Zevra Therapeutics, Inc.
ZVRA
2.2%
+1.1pp
Other financials
Income statement
See full
Revenue
$20.0M
—
Operating income
-$26.6M
+25.0%
Net income
-$24.2M
+26.2%
EPS (diluted)
-$0.45
+60.9%
Balance sheet
See full
Cash & equivalents
$198.8M
-32.5%
Total debt
$61.2M
+137%
Total equity
$341.7M
+17.0%
Total assets
$419.7M
+26.1%
Cash flow
See full
Operating cash flow
-$39.1M
-32.5%
CapEx
$93.0K
-68.9%
Free cash flow
-$39.2M
-31.5%
Valuation
See full
Market cap
$1.48B
+201%
Enterprise value
$1.34B
—
P/S
7.9×
—
Profitability
See full
Operating margin
-71.5%
—
Net margin
-65.4%
—
FCF margin
-65.1%
—
Returns & leverage
See full
Return on equity
-38.7%
—
Debt / equity
0.2×
+0.1×
Current ratio
17.9×
+1.8×